Rosmolen WD, et al. - Since a previous multicenter randomized trial showed that radiofrequency ablation (RFA) significantly reduced risk of neoplastic progression vs surveillance in patients with Barrett’s esophagus (BE) with low-grade dysplasia (LGD), researchers compared quality of life (QOL) and illness perception (IP) between the patients treated with RFA and patients kept under surveillance in the same population. Barrett’s patients with LGD were randomly assigned to RFA or surveillance from June 2007 to June 2011. The questionnaires were completed by 47 patients with ablation and 49 patients with surveillance. A QOL comparable to patients undergoing endoscopic surveillance was reported by patients treated with BE ablation with LGD. However, the ablation group had fewer concerns and a less threatening view of their condition.